|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HEYL |
Gene summary for HEYL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HEYL | Gene ID | 26508 |
| Gene name | hes related family bHLH transcription factor with YRPW motif like | |
| Gene Alias | HESR3 | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9NQ87 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26508 | HEYL | ATC12 | Human | Thyroid | ATC | 4.82e-02 | 1.44e-01 | 0.34 |
| 26508 | HEYL | ATC13 | Human | Thyroid | ATC | 4.66e-32 | 7.95e-01 | 0.34 |
| 26508 | HEYL | ATC4 | Human | Thyroid | ATC | 2.34e-04 | 1.87e-01 | 0.34 |
| 26508 | HEYL | ATC5 | Human | Thyroid | ATC | 6.03e-40 | 8.55e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007207322 | Thyroid | ATC | kidney epithelium development | 68/6293 | 136/18723 | 5.50e-05 | 4.24e-04 | 68 |
| GO:000317012 | Thyroid | ATC | heart valve development | 37/6293 | 65/18723 | 9.43e-05 | 6.91e-04 | 37 |
| GO:003052124 | Thyroid | ATC | androgen receptor signaling pathway | 27/6293 | 44/18723 | 1.49e-04 | 1.03e-03 | 27 |
| GO:007200614 | Thyroid | ATC | nephron development | 69/6293 | 142/18723 | 1.50e-04 | 1.04e-03 | 69 |
| GO:00030075 | Thyroid | ATC | heart morphogenesis | 110/6293 | 246/18723 | 1.76e-04 | 1.20e-03 | 110 |
| GO:0072132 | Thyroid | ATC | mesenchyme morphogenesis | 30/6293 | 52/18723 | 3.08e-04 | 1.94e-03 | 30 |
| GO:00720097 | Thyroid | ATC | nephron epithelium development | 54/6293 | 109/18723 | 4.12e-04 | 2.49e-03 | 54 |
| GO:000317912 | Thyroid | ATC | heart valve morphogenesis | 31/6293 | 55/18723 | 4.33e-04 | 2.59e-03 | 31 |
| GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
| GO:000721915 | Thyroid | ATC | Notch signaling pathway | 79/6293 | 172/18723 | 5.08e-04 | 2.96e-03 | 79 |
| GO:003314414 | Thyroid | ATC | negative regulation of intracellular steroid hormone receptor signaling pathway | 23/6293 | 38/18723 | 6.05e-04 | 3.44e-03 | 23 |
| GO:0003198 | Thyroid | ATC | epithelial to mesenchymal transition involved in endocardial cushion formation | 12/6293 | 16/18723 | 8.59e-04 | 4.68e-03 | 12 |
| GO:000318111 | Thyroid | ATC | atrioventricular valve morphogenesis | 16/6293 | 24/18723 | 9.46e-04 | 5.07e-03 | 16 |
| GO:000328121 | Thyroid | ATC | ventricular septum development | 37/6293 | 71/18723 | 9.80e-04 | 5.21e-03 | 37 |
| GO:000323111 | Thyroid | ATC | cardiac ventricle development | 58/6293 | 123/18723 | 1.23e-03 | 6.46e-03 | 58 |
| GO:000320612 | Thyroid | ATC | cardiac chamber morphogenesis | 57/6293 | 121/18723 | 1.39e-03 | 7.20e-03 | 57 |
| GO:00613265 | Thyroid | ATC | renal tubule development | 46/6293 | 94/18723 | 1.48e-03 | 7.52e-03 | 46 |
| GO:006041111 | Thyroid | ATC | cardiac septum morphogenesis | 35/6293 | 68/18723 | 1.76e-03 | 8.71e-03 | 35 |
| GO:0003197 | Thyroid | ATC | endocardial cushion development | 25/6293 | 45/18723 | 2.00e-03 | 9.59e-03 | 25 |
| GO:0003203 | Thyroid | ATC | endocardial cushion morphogenesis | 21/6293 | 36/18723 | 2.01e-03 | 9.59e-03 | 21 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| HEYL | TREG | Esophagus | ADJ | YWHAH,ARIH2,VWCE, etc. | 1.21e-02 |  |
| HEYL | PERI | Prostate | ADJ | COL18A1,RGS5,PLXDC1, etc. | 7.69e-02 |  |
| HEYL | PERI | Prostate | BPH | COL18A1,RGS5,PLXDC1, etc. | 3.51e-01 |  |
| HEYL | PERI | Prostate | Tumor | COL18A1,RGS5,PLXDC1, etc. | 3.02e-01 |  |
| HEYL | MYOFIB | Stomach | ADJ | PDGFRB,FOXS1,COL18A1, etc. | 2.35e-01 |  |
| HEYL | MYOFIB | Stomach | CAG | PDGFRB,FOXS1,COL18A1, etc. | 2.76e-01 |  |
| HEYL | SMC | Stomach | CAG with IM | PDGFRB,FOXS1,COL18A1, etc. | 3.61e-01 |  |
| HEYL | MYOFIB | Stomach | CSG | PDGFRB,FOXS1,COL18A1, etc. | 1.01e-01 |  |
| HEYL | SMC | Stomach | CSG | PDGFRB,FOXS1,COL18A1, etc. | 2.85e-01 | |
| HEYL | MYOFIB | Stomach | GC | PDGFRB,FOXS1,COL18A1, etc. | 4.25e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HEYL | SNV | Missense_Mutation | novel | c.806G>C | p.Ser269Thr | p.S269T | Q9NQ87 | protein_coding | tolerated_low_confidence(0.09) | benign(0.015) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| HEYL | SNV | Missense_Mutation | c.537N>G | p.Phe179Leu | p.F179L | Q9NQ87 | protein_coding | deleterious(0.03) | benign(0.119) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| HEYL | SNV | Missense_Mutation | novel | c.164N>A | p.Arg55His | p.R55H | Q9NQ87 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-OL-A66J-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HEYL | SNV | Missense_Mutation | novel | c.949T>C | p.Ser317Pro | p.S317P | Q9NQ87 | protein_coding | tolerated_low_confidence(0.06) | benign(0.001) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| HEYL | SNV | Missense_Mutation | novel | c.196T>G | p.Leu66Val | p.L66V | Q9NQ87 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HEYL | SNV | Missense_Mutation | c.422N>A | p.Arg141His | p.R141H | Q9NQ87 | protein_coding | tolerated(0.25) | benign(0.012) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HEYL | SNV | Missense_Mutation | c.443G>A | p.Arg148His | p.R148H | Q9NQ87 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HEYL | SNV | Missense_Mutation | c.764N>T | p.Ala255Val | p.A255V | Q9NQ87 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HEYL | SNV | Missense_Mutation | rs747977443 | c.442C>T | p.Arg148Cys | p.R148C | Q9NQ87 | protein_coding | deleterious(0.02) | possibly_damaging(0.852) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| HEYL | SNV | Missense_Mutation | rs766168978 | c.202N>T | p.Arg68Cys | p.R68C | Q9NQ87 | protein_coding | deleterious(0.01) | benign(0.334) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |